Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies

References

• Reichert JM. Marketed Therapeutic Antibodies Compendium. MAbs. 2012;4:413–15. doi:10.4161/mabs.19931.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13:85–99. doi:10.2174/1574884712666170809124728.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to Watch in 2018. MAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9:63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kato C, Kato A. Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies. J Toxicol Pathol. 2015;28:133–39. doi:10.1293/tox.2015-0031.
   PubMed Web of Science ®Google Scholar
• Zafir-Lavie I, Michaeli Y, Reiter Y. Novel antibodies as anticancer agents. Oncogene. 2007;26:3714–33. doi:10.1038/sj.onc.1210372.
   PubMed Web of Science ®Google Scholar
• Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammag immunoglobulin molecule. Proc Natl Acad Sci U S A. 1969;63:78–85.
   PubMed Web of Science ®Google Scholar
• Reusch D, Tejada ML. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology. 2015;25:1325–34. doi:10.1093/glycob/cwv065.
   PubMed Web of Science ®Google Scholar
• Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab Gp2013 and originator rituximab. BioDrugs. 2013;27:495–507. doi:10.1007/s40259-013-0036-3.
   PubMed Web of Science ®Google Scholar
• Li W, Zhu Z, Chen W, Feng Y, Dimitrov DS. Crystallizable fragment glycoengineering for therapeutic antibodies development. Front Immunol. 2017;8:1554. doi:10.3389/fimmu.2017.01554.
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, et al. Defucosylated Anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42. doi:10.1200/JCO.2011.37.3472.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O‘Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Kiyoshi M, Caaveiro JMM, Tada M, Tamura H, Tanaka T, Terao Y, Morante K, Harazono A, Hashii N, Shibata H, et al. Assessing the heterogeneity of the Fc-Glycan of a therapeutic antibody using an engineered FcγReceptor IIIa-immobilized column. Sci Rep. 2018;8:3955. doi:10.1038/s41598-018-22199-8.
   PubMed Web of Science ®Google Scholar
• Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. 2016;73:69–75. doi:10.1016/j.molimm.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Peschke B, Keller CW, Weber P, Quast I, Lunemann JD. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 2017;8:646. doi:10.3389/fimmu.2017.00646.
   PubMed Web of Science ®Google Scholar
• Liu CP, Tsai TI, Cheng T, Shivatare VS, Wu CY, Wong CH. Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation. Proc Natl Acad Sci U S A. 2018;115:720–25. doi:10.1073/pnas.1718172115.
   PubMed Web of Science ®Google Scholar
• Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2019;11:350–72. doi:10.1080/19420862.2018.1551044.
   PubMed Web of Science ®Google Scholar
• Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc. 2012;134:12308–18. doi:10.1021/ja3051266.
   PubMed Web of Science ®Google Scholar
• Kurogochi M, Mori M, Osumi K, Tojino M, Sugawara S, Takashima S, Hirose Y, Tsukimura W, Mizuno M, Amano J, et al. Glycoengineered monoclonal antibodies with homogeneous glycan (M3, G0, G2, and A2) using a chemoenzymatic approach have different affinities for FcγRIIIa and variable antibody-dependent cellular cytotoxicity activities. PLoS One. 2015;10:e0132848. doi:10.1371/journal.pone.0132848.
   PubMed Web of Science ®Google Scholar
• Tsukimura W, Kurogochi M, Mori M, Osumi K, Matsuda A, Takegawa K, Furukawa K, Shirai T. Preparation and biological activities of anti-HER2 monoclonal antibodies with fully core-fucosylated homogeneous bi-antennary complex-type glycans. Biosci Biotechnol Biochem. 2017;81:2353–59. doi:10.1080/09168451.2017.1394813.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Tanaka T, Gyakushi H, Kobayashi A, Shoda S. Efficient synthesis of sugar oxazolines from unprotected N-acetyl-2-amino sugars by using chloroformamidinium reagent in water. J Org Chem. 2009;74:2210–12. doi:10.1021/jo8024708.
   PubMed Web of Science ®Google Scholar
• Collin M, Olsen A. Endo S, a novel secreted protein from streptococcus pyogenes with endoglycosidase activity on human IgG. Embo J. 2001;20:3046–55. doi:10.1093/emboj/20.12.3046.
   PubMed Web of Science ®Google Scholar
• Collin M, Olsen A. Effect of SpeB and EndoS from streptococcus pyogenes on human immunoglobulins. Infect Immun. 2001;69:7187–89. doi:10.1128/IAI.69.11.7187-7189.2001.
   PubMed Web of Science ®Google Scholar
• Harvey DJ. Fragmentation of negative ions from carbohydrates: part 2. fragmentation of high-mannose N-Linked glycans. J Am Soc Mass Spectrom. 2005;16:631–46. doi:10.1016/j.jasms.2005.01.005.
   PubMed Web of Science ®Google Scholar
• Giddens JP, Lomino JV, Amin MN, Wang LX. Endo-F3 glycosynthase mutants enable chemoenzymatic synthesis of core-fucosylated triantennary complex type glycopeptides and glycoproteins. J Biol Chem. 2016;291:9356–70. doi:10.1074/jbc.M116.721597.
   PubMed Web of Science ®Google Scholar
• Reusch D, Haberger M, Falck D, Peter B, Maier B, Gassner J, Hook M, Wagner K, Bonnington L, Bulau P, et al. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-part 2: mass spectrometric methods. MAbs. 2015;7:732–42. doi:10.1080/19420862.2015.1045173.
   PubMed Web of Science ®Google Scholar
• Ibuki C, Seino Y, Otsuka T, Kimata N, Inami T, Munakata R, Mizuno K. Switching to pitavastatin in statin-treated low Hdl-C patients further improves the lipid profile and attenuates minute myocardial damage. J Clin Med Res. 2012;4:385–92. doi:10.4021/jocmr1108w.
   PubMedGoogle Scholar
• Fritz-Rdzanek A, Grzybowski W, Beta J, Durczynski A, Jakimiuk A. He4 protein and smrp: potential novel biomarkers in ovarian cancer detection. Oncol Lett. 2012;4:385–89. doi:10.3892/ol.2012.757.
   PubMed Web of Science ®Google Scholar
• Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of fcgammariia for the characterization of therapeutic monoclonal antibodies. PLoS One. 2014;9:e95787. doi:10.1371/journal.pone.0095787.
   PubMed Web of Science ®Google Scholar
• Liu H, Nowak C, Andrien B, Shao M, Ponniah G, Neill A. Impact of IgG Fc-oligosaccharides on recombinant monoclonal antibody structure, stability, safety, and efficacy. Biotechnol Prog. 2017;33:1173–81. doi:10.1002/btpr.2498.
   PubMed Web of Science ®Google Scholar
• Liu H, Bulseco GG, Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett. 2006;106:144–53. doi:10.1016/j.imlet.2006.05.011.
   PubMed Web of Science ®Google Scholar
• Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol. 2003;325:979–89.
   PubMed Web of Science ®Google Scholar
• Raju TS. terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20:471–78. doi:10.1016/j.coi.2008.06.007.
   PubMed Web of Science ®Google Scholar
• Harbison AM, Brosnan LP, Fenlon K, Fadda E. Sequence-to-structure dependence of isolated IgG Fc complex biantennary N-glycans: a molecular dynamics study. Glycobiology. 2019;29:94–103. doi:10.1093/glycob/cwy097.
   PubMed Web of Science ®Google Scholar
• Mortensen SA, Sander B, Jensen RK, Pedersen JS, Golas MM, Jensenius JC, Hansen AG, Thiel S, Andersen GR. Structure and Activation of C1, the Complex Initiating the Classical Pathway of the Complement Cascade. Proc Natl Acad Sci U S A. 2017;114:986–91. doi:10.1073/pnas.1616998114.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–73. doi:10.1074/jbc.M210665200.
   PubMed Web of Science ®Google Scholar
• Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One. 2015;10:e0143520. doi:10.1371/journal.pone.0143520.
   PubMed Web of Science ®Google Scholar
• Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Ruger P, Reusch D. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and Adcc activity. PLoS One. 2015;10:e0134949. doi:10.1371/journal.pone.0134949.
   PubMed Web of Science ®Google Scholar
• Roberts JT, Barb AW. A single amino acid distorts the fc gamma receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a. J Biol Chem. 2018. doi:10.1074/jbc.RA118.005273.
   Web of Science ®Google Scholar
• Subedi GP, Barb AW. The structural role of antibody N-glycosylation in receptor interactions. Structure. 2015;23:1573–83. doi:10.1016/j.str.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics. 2010;9:1716–28. doi:10.1074/mcp.M900540-MCP200.
   PubMed Web of Science ®Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs. 2012;4:385–91. doi:10.4161/mabs.19868.
   PubMed Web of Science ®Google Scholar
• Wang S, Ionescu R, Peekhaus N, Leung JY, Ha S, Vlasak J. Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. J Chromatogr A. 2010;1217:6496–502. doi:10.1016/j.chroma.2010.08.044.
   PubMed Web of Science ®Google Scholar
• Bigge JC, Patel TP, Bruce JA, Goulding PN, Charles SM, Parekh RB. Nonselective and efficient fluorescent labeling of glycans using 2-Amino benzamide and anthranilic acid. Anal Biochem. 1995;230:229–38. doi:10.1006/abio.1995.1468.
   PubMed Web of Science ®Google Scholar
• Anumula KR, Dhume ST. High resolution and high sensitivity methods for oligosaccharide mapping and characterization by normal phase high performance liquid chromatography following derivatization with highly fluorescent anthranilic acid. Glycobiology. 1998;8:685–94.
   PubMed Web of Science ®Google Scholar
• Aoyama M, Tada M, Tatematsu KI, Hashii N, Sezutsu H, Ishii-Watabe A. Effects of amino acid substitutions on the biological activity of Anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx Mori). Biochem Biophys Res Commun. 2018;503:2633–38. doi:10.1016/j.bbrc.2018.08.015.
   PubMed Web of Science ®Google Scholar
• Tada M, Tatematsu K, Ishii-Watabe A, Harazono A, Takakura D, Hashii N, Sezutsu H, Kawasaki N. Characterization of Anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx Mori). MAbs. 2015;7:1138–50. doi:10.1080/19420862.2015.1078054.
   PubMed Web of Science ®Google Scholar